April 17, 2014

Bioscience / Biotech

01/16/14

ASU center kicks off inaugural lectures, symposium series on evolutionary health

The ASU Center for Evolution, Medicine and Public Health will host several events to celebrate the center’s launch.

01/16/14

Evolutionary medicine expert joins ASU faculty

Randolph M. Nesse, one of the world’s preeminent researchers and teachers in the field of evolutionary medicine, joins the ASU faculty this semester.

01/16/14

Sludge as new sentinel for human health risks

ASU researchers have outlined a new approach to the identification of potentially harmful, mass-produced chemicals, describing the accumulation in sludge of 123 distinct chemicals of emerging concern.

01/08/14

Selinsky returns to ASU Biodesign Institute as chief operating officer

The Biodesign Institute at ASU has appointed Cheryl Selinsky as senior director and chief operating officer.

01/07/14

First International School of Biomedical Diagnostics breaks new ground

ASU and Dublin City University are joining forces to create a new International School of Biomedical Diagnostics.

12/17/13

ASU partners with San Diego Zoo in conservation research

ASU has launched an unusual collaborative partnership with the San Diego Zoo to assess how changes in an animal's environment influence health and behavior.

12/16/13

Fungal pathogen shows profound effects from spaceflight

At Arizona State University's Biodesign Institute, Cheryl Nickerson and her team have been investigating the intriguing effects of spaceflight on microbial pathogens.

12/13/13

Cyber-bullying, drug-resistant bugs among research crowdfunding campaigns

ASU's new, official crowdfunding platform is helping faculty and student researchers find support for unique and socially beneficial studies.

12/02/13

Sorting good germs from bad in the bacterial world

ASU scientists have developed a microfluidic chip that can sort good germs from bad.

12/02/13

Bioscience / Biotech | Law | News coverage:  Marchant: How the FDA could set personal genetics back decades

ASU law professor Gary Marchant argues that the FDA's effort to stop the services of a personal genetic testing company is a “shortsighted, heavy-handed, double-standard act of paternalism.”

Syndicate content